PFC:D1→BLA | | |
Control | 1.44 ± 0.20 | 5.9 ± 0.2 |
Ipsilateral | 1.47 ± 0.20 | 7.2 ± 0.2 |
Disconnection | 1.48 ± 0.14 | 8.0 ± 2.5 |
PFC:D2→BLA (descending) | | |
Control | 0.69 ± 0.10 | 3.1 ± 1.0 |
Ipsilateral | 1.08 ± 0.16 | 3.2 ± 1.4 |
Disconnection | 1.45 ± 0.27 | 8.8 ± 2.7 |
PFC:D2→BLA (ascending) | | |
Control | 0.47 ± 0.06 | 0.0 ± 0.0 |
Ipsilateral | 0.51 ± 0.06 | 0.1 ± 0.1 |
Disconnection | 0.50 ± 0.06 | 0.4 ± 0.2 |
PFC:D1→NAc | | |
Control | 0.92 ± 0.12 | 2.0 ± 1.2 |
Ipsilateral | 1.37 ± 0.20* | 11.0 ± 4.2* |
Disconnection | 1.42 ± 0.18* | 13.4 ± 3.5* |
PFC:D2→NAc | | |
Control | 0.64 ± 0.05 | 0.4 ± 0.2 |
Ipsilateral | 1.24 ± 0.21* | 7.2 ± 2.4* |
Disconnection | 1.18 ± 0.13* | 5.6 ± 2.2* |
Unilateral D1 antagonist | | |
Saline | 0.80 ± 0.14 | 0.4 ± 0.3 |
SCH 23390 1 μg | 0.68 ± 0.12 | 0.8 ± 0.4 |
Unilateral D2 antagonist | | |
Saline | 0.74 ± 0.12 | 1.0 ± 0.7 |
Eticlopride 1 μg | 0.72 ± 0.08 | 0.6 ± 0.5 |
Unilateral BLA inactivation | | |
Saline | 1.08 ± 0.18 | 4.4 ± 3.8 |
Inactivation | 0.85 ± 0.25 | 2.0 ± 1.5 |
Unilateral NAc inactivation | | |
Saline | 0.74 ± 0.09 | 0.3 ±0.2 |
Inactivation | 0.90 ± 0.15 | 1.9 ±0.8 |
Magnitude discrimination | | |
PFC:D1→NAc | | |
Control | 0.89 ± 0.08 | 0.3 ± 0.2 |
Ipsilateral | 1.37 ± 0.33 | 5.3 ± 2.3 |
Disconnection | 1.17 ± 0.31 | 4.8 ± 3.1 |
PFC:D2→NAc | | |
Control | 0.89 ± 0.08 | 0.3 ± 0.2 |
Ipsilateral | 0.88 ± 0.15 | 0.6 ± 0.3 |
Disconnection | 1.54 ± 0.45 | 5.0 ± 1.6* |